Showing 2351-2360 of 8833 results for "".
Psoriasis Treatment in 2025: More Options, Better Outcomes
https://practicaldermatology.com/issues/august-2025/psoriasis-treatment-in-2025-more-options-better-outcomes/36706/We have better drugs to treat psoriasis than almost any other dermatologic disease state. For patients, it is an excellent time to have psoriasis.Marketing Leading Technologies That Support Your Team
https://practicaldermatology.com/issues/august-2025/marketing-leading-technologies-that-support-your-team/36708/From ChatGPT and other artificial intelligence (AI) platforms to the latest mobile apps, technology continues to transform the already dynamic field of health care.Comorbidities in Vitiligo
https://practicaldermatology.com/issues/august-2025/comorbidities-in-vitiligo/36702/Vitiligo is a chronic, acquired pigmentary disorder characterized by the progressive loss of function or destruction of melanocytes in the skin, hair follicles, and mucous membranes. In this piece, Dr. Brad Glick and colleagues explore comorbidities in vitiligo.Scurvy Following Gastric Bypass
https://practicaldermatology.com/issues/august-2025/scurvy-following-gastric-bypass/36701/This report highlights a unique case of scurvy presentation following gastric bypass surgery. A 39-year-old female presented for outpatient dermatology follow-up for a rash that had been present for several months, affecting the buttocks, extremities, and trunk.DWTV Extra: DermLink Scholars Founder Dr. Kelly Frasier
https://practicaldermatology.com/series/dermwire-tv/DWTV-Extra-DermLink-Scholars-Founder-Dr-Kelly-Frasier/36554/DermLink Scholars Founder and CEO Kelly Frasier, DO, MS, CRC, and Alina G. Bridges, DO, FAAD, discuss the organization and its inaugural virtual conference Saturday, August 2. For more information, go to dermlinkscholars.com.Evaluating Lebrikizumab in Pigmented Skin
https://practicaldermatology.com/series/updates-atopic-dermatitis/evaluating-lebrikizumab-in-pigmented-skin/36490/Andrew Alexis, MD, MPH, discusses new data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from the phase 3b Admirable trial, the first dedicated study for evaluating the efficacy and safety of Lilly's FDA-approved medicine in adult and adolescent patients with pigmented skin andFDA Grants Interchangeability to HADLIMA
https://practicaldermatology.com/series/dermwire-tv/fda-grants-interchangeability-to-hadlima/35962/In this week's DermwireTV, the FDA grants full interchangeability to HADLIMA; new research shows the impact of UV exposure on global skin cancer cases; and coverage from Music City SCALE addresses barriers to patient access to new therapies.Fractional Lasers for NMSC and More
https://practicaldermatology.com/conferences/scale-2025/fractional-lasers-for-nmsc-and-more/35876/Joel L. Cohen, MD, FAAD, and Matthew M. Avram, MD, talk about research involving fractional lasers, including as part of combination treatments for nonmelanoma skin cancer, at Music City SCALE 2025.Procedural Management for HS
https://practicaldermatology.com/programs/practical-dermatology/procedural-management-for-hs/35891/Vivian Shi, MD, talks about procedural management for hidradenitis suppurativa and how to incorporate those procedures with medical management of the condition at Music City SCALE 2025.Rosacea Treatment Options and Strategies
https://practicaldermatology.com/programs/practical-dermatology/rosacea-treatment-options-and-strategies/35893/Joel L. Cohen, MD, FAAD, and Hilary Baldwin, MD, talk at Music City SCALE 2025 about the latest treatment options for rosacea and strategies for getting patient buy-in.